The Precision Peptide Company Inc. PNGAF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 967.44% | -- | -- | 3,850.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 967.44% | -- | -- | 3,850.00% | -- |
| Cost of Revenue | 1,335.71% | -- | -- | 1,590.91% | -- |
| Gross Profit | 789.66% | -- | -- | 4,400.00% | -- |
| SG&A Expenses | 144.37% | 82.57% | 641.19% | 137.19% | 852.85% |
| Depreciation & Amortization | -- | -- | -- | 16,750.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 147.19% | 92.75% | 664.26% | 144.12% | 852.05% |
| Operating Income | -139.91% | -86.41% | -642.05% | -135.53% | -843.44% |
| Income Before Tax | -168.20% | -69.97% | -623.85% | -594.47% | -833.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -168.20% | -69.97% | -623.85% | -594.47% | -833.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -168.20% | -69.97% | -623.85% | -594.47% | -833.46% |
| EBIT | -139.91% | -86.41% | -642.05% | -135.53% | -843.44% |
| EBITDA | -141.95% | -78.13% | -633.91% | -127.21% | -824.12% |
| EPS Basic | -57.40% | 23.93% | -38.12% | -21.67% | -113.92% |
| Normalized Basic EPS | -56.60% | 24.66% | -38.05% | 57.78% | -116.33% |
| EPS Diluted | -57.40% | 23.93% | -38.12% | -21.67% | -113.92% |
| Normalized Diluted EPS | -56.60% | 24.66% | -38.05% | 57.78% | -116.33% |
| Average Basic Shares Outstanding | 70.14% | 124.16% | 425.41% | 470.63% | 334.73% |
| Average Diluted Shares Outstanding | 70.14% | 124.16% | 425.41% | 470.63% | 334.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |